Teva Pharmaceutical Industries Limited (TEVA) Rating Lowered to Neutral at Citigroup Inc.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) was downgraded by equities researchers at Citigroup Inc. from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Wednesday. They presently have a $19.00 target price on the stock, down from their previous target price of $32.00. Citigroup Inc.’s price objective would suggest a potential upside of 11.11% from the company’s current price.

A number of other equities analysts also recently issued reports on the stock. Vetr downgraded shares of Teva Pharmaceutical Industries Limited from a “strong-buy” rating to a “buy” rating and set a $31.94 price target for the company. in a research note on Monday, May 22nd. Deutsche Bank AG reissued a “buy” rating and issued a $28.00 price target (down from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. Credit Suisse Group downgraded shares of Teva Pharmaceutical Industries Limited from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $39.00 to $25.00 in a research note on Friday, August 4th. Barclays PLC decreased their price target on shares of Teva Pharmaceutical Industries Limited from $38.00 to $23.00 and set an “equal weight” rating for the company in a research note on Monday, August 7th. Finally, Mizuho reissued a “hold” rating and issued a $30.00 price target on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 2nd. Three investment analysts have rated the stock with a sell rating, twenty have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Teva Pharmaceutical Industries Limited currently has a consensus rating of “Hold” and an average price target of $36.73.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 17.10 on Wednesday. The company’s market capitalization is $17.37 billion. Teva Pharmaceutical Industries Limited has a 12 month low of $16.81 and a 12 month high of $53.96. The company’s 50-day moving average price is $27.91 and its 200 day moving average price is $31.10.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The business had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. During the same quarter in the previous year, the company earned $1.25 earnings per share. The business’s quarterly revenue was up 12.9% on a year-over-year basis. Analysts forecast that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.com-unik.info/2017/08/18/teva-pharmaceutical-industries-limited-teva-rating-lowered-to-neutral-at-citigroup-inc.html.

A number of large investors have recently added to or reduced their stakes in TEVA. San Francisco Sentry Investment Group CA bought a new stake in Teva Pharmaceutical Industries Limited during the second quarter valued at about $106,000. Bronfman E.L. Rothschild L.P. boosted its stake in Teva Pharmaceutical Industries Limited by 7.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock valued at $116,000 after buying an additional 261 shares during the period. Kistler Tiffany Companies LLC boosted its stake in Teva Pharmaceutical Industries Limited by 74.7% in the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock valued at $122,000 after buying an additional 1,571 shares during the period. FNY Managed Accounts LLC bought a new stake in Teva Pharmaceutical Industries Limited during the first quarter valued at about $123,000. Finally, Sterling Investment Advisors Ltd. boosted its stake in Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock valued at $125,000 after buying an additional 100 shares during the period. 56.04% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

What are top analysts saying about Teva Pharmaceutical Industries Limited? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Teva Pharmaceutical Industries Limited and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit